Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: Thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal

Thyroid

Volumn 16, Issue 10, 2006, Pages 1041-1045

  Guilhem, Isabelle ^a   Massart, Catherine ^b   Poirier, Jean Yves ^a   Maugendre, Didier ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; LIOTHYRONINE; THYROID PEROXIDASE ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; ARTICLE; DRUG MEGADOSE; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SEROPREVALENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTITHYROID AGENTS; AUTOANTIBODIES; CARBIMAZOLE; FEMALE; GRAVES DISEASE; HUMANS; IODIDE PEROXIDASE; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RECEPTORS, THYROTROPIN;

EID: 33846451449     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.1041     Document Type: Article

References (24)

1. Weetman AP 2000 Graves' disease. N Engl J Med 343:1236-1248.
2. Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802-835.
3. Edan G, Massart C, Hody B, Poirier JY, Le Reun M, Hespel JP, Leclech G, Simon M 1989 Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease. BMJ 298:359-361.
4. Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK 1992 Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. Clin Endocrinol (Oxf) 36:585-590.
5. Feldt-Rasmussen U, Schleusener H, Carayon P 1994 Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78:98-102.
6. Davies TF, Roti E, Braverman LE, DeGroot LJ 1998 Thyroid controversy-stimulating antibodies. J Clin Endocrinol Metab 83:3777-3785.
7. Orgiazzi J 2000 Anti-TSH receptor antibodies in clinical practice. Endocrinol Metab Clin North Am 29:339-355, vii.
8. Czarnocka B, Ruf J, Ferrand M, Carayon P, Lissitzky S 1985 Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases. FEBS Lett 190:147-152.
9. Portmann L, Hamada N, Heinrich G, DeGroot LJ 1985 Antithyroid peroxidase antibody in patients with autoimmune thyroid disease: possible identity with anti-microsomal antibody. J Clin Endocrinol Metab 61:1001-1003.
10. Beever K, Bradbury J, Phillips D, McLachlan SM, Pegg C, Goral A, Overbeck W, Feifel G, Smith BR 1989 Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem 35:1949-1954.
11. Maugendre D, Massart C 2001 Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 54:89-96.
12. Massart C, Hody B, Mouchel L, Edan G, Nicol M 1986 Assays for thyrotropin-receptor binding and thyroid-stimulating antibodies in sera from patients with Graves' disease. Clin Chem 32:1332-1335.
13. Mariotti S, Caturegli P, Piccolo P, Barbesino G, Pinchera A 1990 Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 71:661-669.
14. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R 1980 Carbimazole and the autoimmune response in Graves' disease. N Engl J Med 303:302-307.
15. Tamaki H, Amino N, Iwatani Y, Tachi J, Mitsuda N, Tanizawa O, Miyai K 1989 Discordant changes in serum anti-TSH receptor antibody and antithyroid microsomal antibody during pregnancy in autoimmune thyroid diseases. Thyroidology 1:73-77.
16. de Forteza R, Smith CU, Amin J, McKenzie JM, Zakarija M 1994 Visualization of the thyrotropin receptor on the cell surface by potent autoantibodies. J Clin Endocrinol Metab 78:1271-1273.
17. Jaume JC, Kakinuma A, Chazenbalk GD, Rapoport B, McLachlan SM 1997 Thyrotropin receptor autoantibodies in serum are present at much lower levels than thyroid peroxidase autoantibodies: analysis by flow cytometry. J Clin Endocrinol Metab 82:500-507.
18. Kim WB, Chung HK, Lee HK, Kohn LD, Tahara K, Cho BY 1997 Changes in epitopes for thyroid-stimulating antibodies in Graves' disease sera during treatment of hyperthyroidism: therapeutic implications. J Clin Endocrinol Metab 82:1953-1959.
19. Ando T, Latif R, Pritsker A, Moran T, Nagayama Y, Davies TF 2002 A monoclonal thyroid-stimulating antibody. J Clin Invest 110:1667-1674.
20. Sanders J, Jeffreys J, Depraetere H, Richards T, Evans M, Kiddie A, Brereton K, Groenen M, Oda Y, Furmaniak J, Rees Smith B 2002 Thyroid-stimulating monoclonal antibodies. Thyroid 12:1043-1050.
21. Sanders J, Evans M, Premawardhana LD, Depraetere H, Jeffreys J, Richards T, Furmaniak J, Rees Smith B 2003 Human monoclonal thyroid stimulating autoantibody. Lancet 362:126-128.
22. Costagliola S, Bonomi M, Morgenthaler NG, Van Durme J, Panneels V, Refetoff S, Vassart G 2004 Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. Mol Endocrinol 18:3020-3034.
23. Takaichi Y, Tamai H, Honda K, Nagai K, Kuma K, Nakagawa T 1989 The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs. J Clin Endocrinol Metab 68:1097-1100.
24. Hirota Y, Tamai H, Hayashi Y, Matsubayashi S, Matsuzuka F, Kuma K, Kumagai LF, Nagataki S 1986 Thyroid function and histology in forty-five patients with hyperthyroid Graves' disease in clinical remission more than ten years after thionamide drug treatment. J Clin Endocrinol Metab 62:165-169.